Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19773023 | 0.88 | DRD2 (1.00) | DRD2MEN1KMT2AATMDRD4 | |
| SCHEMBL6505862 | 0.86 | DRD2 (0.71) | DRD2MEN1KMT2AATMHTR2C | |
| SCHEMBL12897535 | 0.84 | DRD2 (0.69) | DRD2MEN1KMT2AATMHTR2C | |
| SCHEMBL12125022 | 0.83 | DRD2 (0.59) | DRD2MEN1KMT2AHTR2CDRD4 | |
| SCHEMBL9001267 | 0.83 | DRD2 (0.76) | DRD2MEN1KMT2AATMHTR2C | |
| SCHEMBL4747037 | 0.83 | DRD2 (0.76) | DRD2MEN1KMT2AATMHTR2C | |
| SCHEMBL12897166 | 0.82 | DRD2 (0.66) | DRD2MEN1KMT2AATMHTR2C | |
| SCHEMBL4744663 | 0.82 | DRD2 (0.66) | DRD2MEN1KMT2AATMHTR2C | |
| SCHEMBL10819400 | 0.82 | DRD2 (0.55) | DRD2MEN1KMT2AATMMAPK1 | |
| SCHEMBL824153 | 0.81 | DRD2 (0.69) | DRD2MEN1KMT2AATMHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| EP-0898569-A1 | PIPERIDINES AND PYRROLIDINES | MERCK PATENT GmbH (DE) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040038-A1 | PIPERIDINES AND PYRROLIDINES | MERCK PATENT GMBH (DE) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | DRD2 211/4885MEN1 4699/4885KMT2A 1176/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 202/4885MEN1 4777/4885KMT2A 988/4885 |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 202/4885MEN1 4777/4885KMT2A 988/4885 |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 147/4885MEN1 4794/4885KMT2A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.